22.00

1.43% -0.32

Biodesix Inc (BDSX)

Overview News Price History Option Chain Financials Discussions Forecast

Biodesix Inc stock is traded at $22.00, with a volume of 90,514. It is down -1.43% in the last 24 hours and up +17.84% over the past month. Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

Previous Close:

$22.32

Open:

$22

24h Volume:

90,514

Relative Volume:

1.19

Market Cap:

$227.83M

Revenue:

$96.10M

Net Income/Loss:

$-31.96M

P/E Ratio:

-5.4635

EPS:

-4.0267

Net Cash Flow:

$-25.27M

1W Performance:

+8.96%

1M Performance:

+17.84%

6M Performance:

+87.39%

1Y Performance:

+163.35%

1-Day Range:

$22.00

$23.80

1-Week Range:

$19.09

$24.02

52-Week Range:

$5.26

$24.92

Biodesix Inc Stock (BDSX) Company Profile

Name

Biodesix Inc

Sector

Healthcare (1071)

Industry

Diagnostics & Research (48)

Phone

303-417-0500

Address

919 WEST DILLON ROAD, LOUISVILLE

Employee

334

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

BDSX's Discussions on Twitter

Compare BDSX vs TMO, DHR, IDXX, A, NTRA

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BDSX Biodesix Inc	22.00	227.83M	96.10M	-31.96M	-25.27M	-4.0267
TMO Thermo Fisher Scientific Inc	568.26	211.18B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	191.50	134.62B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	544.32	42.94B	4.45B	1.10B	1.06B	13.59
A Agilent Technologies Inc	138.57	39.14B	7.23B	1.41B	1.09B	4.979
NTRA Natera Inc	261.99	37.52B	2.50B	-226.32M	71.51M	-1.6412

Biodesix Inc Stock (BDSX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-27-26	Upgrade	William Blair	Mkt Perform → Outperform
May-14-25	Downgrade	William Blair	Outperform → Mkt Perform
Sep-16-24	Initiated	Scotiabank	Sector Outperform
Jul-26-24	Initiated	Craig Hallum	Buy
May-13-24	Initiated	TD Cowen	Buy
May-03-24	Initiated	Lake Street	Buy
Nov-17-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-23-20	Initiated	BTIG Research	Buy
Nov-23-20	Initiated	Canaccord Genuity	Buy
Nov-23-20	Initiated	Morgan Stanley	Overweight
Nov-23-20	Initiated	William Blair	Outperform

View All

Biodesix Inc Stock (BDSX) Latest News

Jul 24, 2026

BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? - TradingView

Jul 24, 2026

Jul 22, 2026

Biodesix to report Q2FY26 results on August 5, 2026 - scanx.trade

Jul 22, 2026

Biodesix to Report Second Quarter 2026 Financial Results on August 5 - Quiver Quantitative

Jul 22, 2026

Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026 - Caledonian Record

Jul 22, 2026

Biodesix management will give a business update on Aug. 5 - Stock Titan

Jul 22, 2026

Jul 19, 2026

Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Jul 19, 2026

Jul 13, 2026